See more : Energem Resources Inc. (ENMFF) Income Statement Analysis – Financial Results
Complete financial analysis of InfuSystem Holdings, Inc. (INFU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of InfuSystem Holdings, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- IPH Limited (IPHLF) Income Statement Analysis – Financial Results
- Blue Label Telecoms Limited (BLU.JO) Income Statement Analysis – Financial Results
- Bodal Chemicals Limited (BODALCHEM.BO) Income Statement Analysis – Financial Results
- Nippon Carbon Co., Ltd. (NCRBF) Income Statement Analysis – Financial Results
- Akasaka Diesels Limited (6022.T) Income Statement Analysis – Financial Results
InfuSystem Holdings, Inc. (INFU)
About InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, hospital market, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 125.79M | 109.91M | 102.38M | 97.39M | 81.12M | 67.14M | 71.08M | 70.50M | 72.13M | 66.49M | 62.28M | 58.83M | 54.64M | 47.23M | 38.96M | 35.42M | 6.58M | 0.00 | 0.00 |
| Cost of Revenue | 62.68M | 47.34M | 42.19M | 38.63M | 34.23M | 28.12M | 27.72M | 25.76M | 20.94M | 19.13M | 18.60M | 15.92M | 19.28M | 13.68M | 10.33M | 9.19M | 1.62M | 0.00 | 0.00 |
| Gross Profit | 63.11M | 62.57M | 60.20M | 58.76M | 46.88M | 39.02M | 43.36M | 44.74M | 51.18M | 47.35M | 43.68M | 42.91M | 35.36M | 33.55M | 28.64M | 26.22M | 4.96M | 0.00 | 0.00 |
| Gross Profit Ratio | 50.17% | 56.93% | 58.80% | 60.33% | 57.80% | 58.12% | 61.01% | 63.46% | 70.97% | 71.22% | 70.13% | 72.94% | 64.71% | 71.03% | 73.50% | 74.05% | 75.39% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 45.38M | 46.08M | 42.26M | 35.20M | 29.02M | 24.85M | 25.20M | 24.63M | 23.78M | 19.99M | 18.97M | 23.06M | 17.99M | 20.62M | 12.22M | 11.77M | 4.89M | 919.22B | 0.00 |
| Selling & Marketing | 12.65M | 12.26M | 10.78M | 9.66M | 9.93M | 9.11M | 9.78M | 9.66M | 10.42M | 9.75M | 9.66M | 9.86M | 9.37M | 7.09M | 5.26M | 4.66M | 649.00K | -919.20B | 0.00 |
| SG&A | 58.03M | 58.34M | 53.04M | 44.86M | 38.96M | 33.95M | 34.98M | 34.29M | 34.20M | 29.73M | 28.63M | 32.93M | 27.36M | 27.71M | 17.48M | 16.42M | 6.12M | 20.82M | 24.48K |
| Other Expenses | 990.00K | 2.58M | 4.34M | 5.08M | 4.40M | -37.00K | -113.00K | 6.00K | 13.00K | 13.00K | 301.00K | -141.00K | 6.76M | 6.77M | 5.83M | 5.01M | 6.46M | 20.82M | 0.00 |
| Operating Expenses | 59.02M | 60.92M | 57.38M | 49.93M | 43.36M | 38.60M | 46.18M | 43.77M | 42.32M | 38.02M | 37.78M | 40.91M | 34.12M | 34.48M | 23.31M | 21.44M | 6.46M | 20.82M | 24.48K |
| Cost & Expenses | 121.70M | 108.26M | 99.56M | 88.56M | 77.59M | 66.72M | 73.90M | 69.52M | 63.26M | 57.16M | 56.38M | 56.83M | 53.40M | 48.17M | 33.64M | 30.63M | 8.08M | 20.82M | 24.48K |
| Interest Income | 0.00 | 1.40M | 1.38M | 1.26M | 1.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 36.00K | 3.88M | 3.20M | 0.00 |
| Interest Expense | 2.17M | 1.40M | 1.38M | 1.26M | 1.90M | 1.42M | 1.33M | 1.34M | 1.71M | 3.13M | 3.50M | 3.34M | 2.19M | 3.35M | 3.50M | 3.77M | 774.00K | 1.30K | 300.00 |
| Depreciation & Amortization | 12.51M | 13.36M | 14.63M | 14.03M | 12.34M | 11.31M | 12.52M | 10.74M | 8.24M | 6.14M | 8.03M | 8.40M | 9.05M | 8.60M | 6.44M | 6.40M | 862.00K | 6.66M | 0.00 |
| EBITDA | 16.50M | 15.09M | 17.15M | 22.82M | 15.77M | 11.69M | 8.60M | 11.72M | 13.94M | 15.49M | 14.23M | 9.45M | -57.34M | 7.75M | 11.69M | 20.40M | -635.00K | -6.82M | -24.48K |
| EBITDA Ratio | 13.11% | 13.55% | 16.86% | 23.44% | 19.44% | 17.41% | 13.49% | 16.63% | 23.74% | 23.29% | 22.85% | 17.44% | 18.82% | 16.21% | 30.22% | 31.70% | 40.40% | 0.00% | 0.00% |
| Operating Income | 4.09M | 1.65M | 2.82M | 8.83M | 3.53M | 415.00K | -3.81M | 974.00K | 8.86M | 9.33M | 5.90M | 2.00M | -66.36M | -938.00K | 5.33M | 4.79M | -1.50M | -20.82M | -24.48K |
| Operating Income Ratio | 3.25% | 1.50% | 2.75% | 9.06% | 4.35% | 0.62% | -5.36% | 1.38% | 12.29% | 14.03% | 9.47% | 3.40% | -121.45% | -1.99% | 13.67% | 13.51% | -22.74% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.24M | -1.52M | -1.56M | -1.28M | -2.00M | -1.46M | -1.45M | -1.34M | -3.29M | -3.12M | -3.20M | -4.15M | -2.22M | -2.29M | -3.58M | 6.08M | -189.00K | -6,821.45B | 0.00 |
| Income Before Tax | 1.85M | 130.00K | 1.26M | 7.54M | 1.52M | -1.04M | -5.26M | -364.00K | 5.57M | 6.21M | 2.70M | -2.15M | -68.58M | -3.22M | 1.75M | 10.87M | -1.69M | -6.82M | 0.00 |
| Income Before Tax Ratio | 1.47% | 0.12% | 1.23% | 7.75% | 1.88% | -1.55% | -7.40% | -0.52% | 7.73% | 9.34% | 4.34% | -3.66% | -125.51% | -6.82% | 4.49% | 30.68% | -25.62% | 0.00% | 0.00% |
| Income Tax Expense | 979.00K | 112.00K | -163.00K | -9.79M | 163.00K | 53.00K | 15.45M | -142.00K | 1.83M | 2.85M | 1.03M | -663.00K | -23.13M | -1.37M | 977.00K | 907.00K | 1.11M | 1.04M | 24.78K |
| Net Income | 872.00K | 18.00K | 1.42M | 17.33M | 1.36M | -1.10M | -20.71M | -222.00K | 3.74M | 3.36M | 1.67M | -1.49M | -45.44M | -1.85M | 774.00K | 9.96M | -2.80M | -7.86M | -24.78K |
| Net Income Ratio | 0.69% | 0.02% | 1.39% | 17.80% | 1.68% | -1.63% | -29.13% | -0.31% | 5.19% | 5.05% | 2.68% | -2.53% | -83.17% | -3.92% | 1.99% | 28.12% | -42.48% | 0.00% | 0.00% |
| EPS | 0.04 | 0.00 | 0.07 | 0.86 | 0.07 | -0.05 | -0.91 | -0.01 | 0.17 | 0.15 | 0.08 | -0.07 | -2.16 | -0.09 | 0.04 | 0.56 | -0.15 | -0.58 | -0.01 |
| EPS Diluted | 0.04 | 0.00 | 0.06 | 0.80 | 0.07 | -0.05 | -0.91 | -0.01 | 0.16 | 0.15 | 0.08 | -0.07 | -2.16 | -0.09 | 0.04 | 0.53 | -0.15 | -0.58 | -0.01 |
| Weighted Avg Shares Out | 21.02M | 20.65M | 20.52M | 20.11M | 19.73M | 21.42M | 22.74M | 22.20M | 22.41M | 22.15M | 21.87M | 21.27M | 21.07M | 19.72M | 18.61M | 17.94M | 18.30M | 13.66M | 3.25M |
| Weighted Avg Shares Out (Dil) | 21.65M | 21.55M | 22.05M | 21.72M | 20.84M | 21.42M | 22.74M | 22.62M | 22.84M | 22.55M | 22.07M | 21.43M | 21.07M | 19.72M | 18.93M | 18.67M | 18.30M | 13.66M | 3.25M |
How One Health System Combines Telemedicine and Hands-on Care
Meridian Ohc Partners, Lp Sells 95,529 Shares of InfuSystem Holdings Inc (NYSEAMERICAN:INFU) Stock
Telerehabilitation Market to Reach USD 9.13 Billion by 2027; Technological Advancement in Healthcare Services to Augment Growth, says Fortune Business Insights™
Lymphatic Education & Research Network Announces First Centers of Excellence
Global Wound Silicone Drainage System Market 2020 Key Players, Industry Size, Share, Segmentation, Comprehensive Analysis and Forecast by 2025
Wipro Extends Partnership with VMware to Deliver BoundaryLess Enterprise Solution
MRI Safe Biopsy Needle Market Insights and Global Outlook During 2021 to 2026; Argon Medical Devices, Somatex Medical Technologies, BD, Sterylab
Medical Products Market Share – Industry Analysis, Growth, Trends, Product, Top Key Players and Regional Forecast 2020-2026
InfuSystem Holdings Inc. (INFU) CEO Rich DiIorio on Q1 2020 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports